Search
Pensacola, FL Paid Clinical Trials
A listing of 106 clinical trials in Pensacola, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
25 - 36 of 106
There are currently 106 clinical trials in Pensacola, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Nemours Children's Clinic - Pensacola, Sacred Heart Hospital, Retina Specialty Institute and Sacred Heart Cancer Center at Sacred Heart Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
07/17/2025
Locations: Avanza Medical Research Center, Pensacola, Florida
Conditions: Episodic Migraine
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/17/2025
Locations: Sacred Heart Hospital, Pensacola, Florida
Conditions: Ischemic Stroke; Ischemic Attack, Transient
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/17/2025
Locations: Avanza Medical Research Center, Pensacola, Florida
Conditions: Idiopathic Pulmonary Fibrosis
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Recruiting
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/17/2025
Locations: Retina Specialty Institute, Pensacola, Florida
Conditions: Geographic Atrophy, Macular Degeneration
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Recruiting
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/16/2025
Locations: Emerald Coast Neurology/Synergy Clinical Research, Pensacola, Florida
Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Study With Phage for CF Subjects With Pseudomonas Lung Infection
Recruiting
The goal of this Phase 2b clinical trial is to see if nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa (PsA) lung infection in CF subjects. The primary goal is to see if 8 weeks of twice daily BX004 can reduce the amount of PsA in the sputum compared to placebo (on top of background CF therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Avanza Medical Center, Pensacola, Florida
Conditions: Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-II
Recruiting
This study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of acute pulmonary embolism.
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
07/15/2025
Locations: Ascension Sacred Heart, Pensacola, Florida
Conditions: Pulmonary Embolism
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/15/2025
Locations: Retina Specialty Institute, Pensacola, Florida
Conditions: Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Recruiting
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Ascension Sacred Heart, Pensacola, Florida
Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Recruiting
This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/14/2025
Locations: Retina Specialty Institute, Pensacola, Florida
Conditions: Neovascular Age-related Macular Degeneration
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Woodlands Medical Specialists, Pensacola, Florida
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Recruiting
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028.
The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
07/14/2025
Locations: Local Institution - 1012, Pensacola, Florida
Conditions: Psychosis Associated With Alzheimer's Disease
25 - 36 of 106